Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24652907 | 0.88 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1CD274CYP1A2 | |
| SCHEMBL24066812 | 0.88 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1CD274CYP1A2 | |
| SCHEMBL20811300 | 0.88 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1CD274CYP1A2 | |
| SCHEMBL23346145 | 0.83 | AGTR2 (0.46) | ALDH1A1MAPK1L3MBTL1HTR2CCYP1A2 | |
| SCHEMBL18347538 | 0.82 | MAPT (0.55) | CD274MAOAMAOBAGTR2 | |
| SCHEMBL24066813 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MAPK1L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL22404766 | 0.79 | POLB (0.46) | ALDH1A1MAPK1L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL29303854 | 0.79 | POLB (0.46) | ALDH1A1MAPK1L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL25832810 | 0.79 | POLB (0.46) | ALDH1A1MAPK1L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL6121682 | 0.79 | POLB (0.53) | HTR2CNPC1RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885MAPK1 1704/4885L3MBTL1 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.